Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine

BMC Neurology

Table 5 Socioeconomic gains, EUR GDP contribution per patient initiating treatment per year

	Chronic migraine		High-frequency episodic migraine		Low-frequency episodic migraine
	Baseline	Gain	Baseline	Gain	Baseline	Gain
Absenteeism	6,325	1,582	5,118	1,280	4,223	1,056
Presenteeism	24,624	3,297	28,922	3,872	33,171	4,441
Working part-time	12,905	1,625	7,995	1,006	8,515	1,072
Labour market participation	5,723	1,662	4,324	266	1,470	158
Educational attainment	24,633	1,913	34,651	1,456	39,083	1,168
Career choice	27,579	3,250	37,224	2,568	53,765	2,052
Total	101,791	13,329	118,233	10,449	140,227	9,947

Baseline values for these parameters are the average earnings for patients replying “yes” to the question, scaled to an average for all patients. I.e., if patients working part-time earn an average of €50,000 and 50% are working part-time, the average effect across all patients is €50,000 * 50% = €25,000. GDP Gross domestic product.
Totals may not correspond with the sum of the separate figures due to rounding

ISSN: 1471-2377